ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million
21 Oct, 2021
– TechsoMed has raised $7m in Series B financing led by Axil Capital.
– The company is developing a first of its kind AI and Algorithm powered real-time tissue damage imaging technology.
– TechsoMed is collaborating with leading medical centers world-wide, in efforts to secure regulatory approval for its BioTrace system in liver tumor ablation through the De Novo process established by the FDA. In parallel, the BioTrace system is also being developed to support cardiac and pain ablation procedures.